

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/735,592

ATTY. DOCKET NO.: C1037.70038US01

FILING DATE: December 11, 2003

CONFIRMATION NO.: 2533

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield



## U.S. PATENT DOCUMENTS

Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
	Number	Kind Code		
A301	5,416,203		Letsinger	05-16-1995
A302	5,514,788		Bennett et al.	05-07-1996
A301	5,527,899		Froehler	06-18-1996
A304	5,587,361		Cook et al.	12-24-1996
A305	5,877,309		McKay et al.	03-02-1999
A306	5,594,122		Friesen	01-14-1997
A307	5,929,226		Padmapriya et al.	07-27-1999
A306	6,030,954		Wu et al.	02-29-2000
A309	6,221,882	B1	Macfarlane	04-24-2001
A310	6,399,630	B1	Macfarlane	06-04-2002
A311	6,476,000	B1	Agrawal et al.	11-05-2002
A312	6,620,805	B1	Takle et al.	09-16-2003
A311	6,815,429	B2	Agrawal	11-09-2004
A315	7,049,302	B1	Kensil	05-23-2006
A315	7,105,495	B2	Agrawal et al.	09-12-2006
A315	7,129,222	B2	Van Nest et al.	10-31-2006
A317	7,183,111	B2	Van Nest et al.	02-27-2007
A318	7,223,741	B2	Krieg	05-29-2007
A318	7,250,403	B2	Van Nest et al.	07-31-2007
A320	7,271,156	B2	Krieg et al.	07-18-2007
A321	2002-0168340	A1	Agrawal	11-14-2002
A322	2003-0064945	A1	Akhtar et al.	04-03-2003
A323	2003-0212029	A1	Agrawal et al.	11-13-2003
A320	2006-0105979	A1	Agrawal et al.	05-18-2006
A325	2006-0154890	A1	Bratzler et al.	07-13-2006
A326	2006-0172966	A1	Lipford et al.	08-03-2006
A327	2006-0188913	A1	Krieg et al.	08-24-2006
A328	2006-0211639	A1	Bratzler et al.	09-21-2006
A329	2006-0211644	A1	Krieg et al.	09-21-2006
A330	2006-0217328	A1	Kandimalla et al.	09-28-2006
A331	2006-0229271	A1	Krieg et al.	10-12-2006
A332	2006-0241076	A1	Uhlmann et al.	10-26-2006

EXAMINER:

/N. M. Minnifield/ (03/09/2009)

DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

<p>Sheet 2 of 4</p>				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	

A333	2006-0246035	A1	Ahlwalia et al.	11-02-2006
A334	2006-0286070	A1	Hartmann et al.	12-21-2006
A335	2006-0287263	A1	Davis et al.	12-21-2006
A336	2007-0009482	A1	Krieg et al.	01-11-2007
A337	2007-0010470	A1	Krieg et al.	01-11-2007
A338	2007-0037767	A1	Bratzler et al.	02-15-2007
A339	2007-0065467	A1	Krieg et al.	03-22-2007
A340	2007-0066553	A1	Krieg et al.	03-22-2007
A341	2007-0066554	A1	Krieg et al.	03-22-2007
A342	2007-0078104	A1	Krieg et al.	04-05-2007
A343	2007-0129320	A9	Davis et al.	06-07-2007
A344	2007-0142315	A1	Forsbach et al.	06-21-2007
A345	2007-0184465	A1	Wagner et al.	08-09-2007
A346	2007-0202128	A1	Krieg et al.	08-30-2007
A347	2007-0224210	A1	Krieg et al.	09-27-2007
A348	2007-0232622	A1	Lipford et al.	10-04-2007
A349	2008-0009455	A9	Krieg et al.	01-10-2008

## FOREIGN PATENT DOCUMENTS

Examiner's Initials <sup>#</sup>	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B90	WO	95/03407		Gen-Probe Incorporated	02-02-1995	
	B91	WO	99/63975	A2	Biognostik Gesellschaft Fur Biomolekular Diagnostik MBH	12-16-1999	
	B92	WO	00/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000	
	B93	WO	00/67023	A1	CPG Immunopharmaceuticals GMBH	11-09-2000	
	B94	WO	02/036767	A3	INEX Pharmaceuticals Corporation	05-10-2002	
	B95	WO	2006/080946	A2	Coley Pharmaceutical GMBH	08-03-2006	
	B96	WO	2007/031877	A2	Coley Pharmaceutical GMBH	03-22-2007	
	B97	WO	2007/038720	A2	Coley Pharmaceutical GMBH	04-05-2007	

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials <sup>#</sup>	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C314	Press Release, January 2007, "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy".	

EXAMINER:

/N. M. Minnifield/ (03/09/2009)

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	3	of	4
-------	---	----	---

APPLICATION NO.:	10/735,592	ATTY. DOCKET NO.:	C1037.70038US01
FILING DATE:	December 11, 2003	CONFIRMATION NO.:	2533
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1645	EXAMINER:	Nita M. Minnifield

C315	Press Release, June 2007. "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer".	
C316	BENNETT, Intracellular delivery of oligonucleotides with cationic liposomes. In: Delivery Strategies for Antisense Oligonucleotide Therapeutics. Akthar, Ed. 1995:223-32.	
C317	BHAGAT et al., CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun. 2003 Jan 24;300(4):853-61.	
C318	CHO et al., Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a t-helper cell-independent mechanism. Nature. 2000 May; 18:509-14.	
C319	DAVIS et al., DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Mt Sinai J Med. 1999 Mar;66(2):84-90. Review.	
C320	HORNER et al., Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant. Clin Immunol. 2000 Apr;95(1 Pt 2):S19-29.	
C321	KLINMAN et al., CpG DNA: recognition by and activation of monocytes. Microbes Infect. 2002 Jul;4(9):897-901.	
C322	KRIEG, Now I know my CpGs. Trends Microbiol. 2001 Jun;9(6):249-52.	
C323	LEE et al., Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials. J Immunol. 2000 Oct 1;165(7):3631-9.	
C324	LI et al., Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine. 2001 Oct 12;20(1-2):148-57.	
C325	LIPFORD et al., Poly-guanosine motifs costimulate antigen-reactive CD8 T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines. Immunology. 2000 Sep;101(1):46-52.	
C326	MAURER et al., CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol. 2002 Aug;32(8):2356-64.	
C327	NORMAN et al., Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation. Gene Ther. 2000;7:1425-30.	
C328	OEHEM et al., Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA. Immunology. 2000 Feb;99(2):163-9.	
C329	OXENIUS et al., CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol. 1999 May;73(5):4120-6.	
C330	SHIROTA et al., Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol. 2001 Jul 1;167(1):66-74.	
C331	TOKUNAGA, Response of the organism to DNA - With a focus on immunostimulatory DNA. Kansen Ensho Meneki. 2001 Autumn; 31(3): 1-12. Japanese.	
C332	UHLMANN et al., Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel. 2003 Mar;6(2):204-17.	
C333	VON HUNOLSTEIN et al., The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine. 2001 Apr 30;19(23-24):3058-66.	
C334	WHALEN et al., DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Ann N Y Acad Sci. 1995 Nov 27;772:64-76.	

EXAMINER:

/N. M. Minnifield/ (03/09/2009)

DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.		
				GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield	
Sheet	4	of	4			

	C335	WHITMORE et al., Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. <i>Canc Immun Immunother.</i> 2001;50:503-14.	
	C336	YU et al., 'Immunomers'—novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. <i>Nucleic Acids Res.</i> 2002 Oct 15;30(20):4460-9.	
	C337	YU et al., Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. <i>Bioorg Med Chem Lett.</i> 2001 Sep 3;11(17):2263-7.	
	C338	ZHANG et al., Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. <i>Antimicrob Agents Chemother.</i> 1999 Feb;43(2):347-53.	
	C339	ZHAO et al., Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. <i>Bioorg Med Chem Lett.</i> 2000 May 15;10(10):1051-4. Abstract Only.	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:  /N. M. Minnifield/ (03/09/2009)	DATE CONSIDERED:
--	------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.